EDO is a company focused on developing early stage assets in oncology. EDO is committed to increasing the treatment options available for cancer patients to help improve and extend their lives.
EDO collaborates with its worldwide network of clinical connections and experienced partners to successfully license-in and develop competitively differentiated preclinical stage programmes for its compounds across a range of cancer types. EDO’s focus on highly-selective inhibitors and targeted medicines, supports its strategy of developing cost-effective and safety-enhanced treatments.
As a privately-funded company with strength in rapid decision making, commercial flexibility and excellent execution, EDO is an ideal partner for biotech companies. By focusing on cancer types with limited available treatment options, EDO aims to maximise the potential impact for patients with unmet needs.